Genomic Health, Janssen Partner to Advance Test Predicting Best Treatment for Low-Risk Prostate Cancer
News
Genomic Health announced has entered a multi-year agreement with Janssen Pharmaceuticals to evaluate its genomic expression test intended to aid in the treatment of recently diagnosed and low-risk prostate cancer patients. As ... Read more